Paper75339
In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis.
Vincent A and 3 others. Lancet, 1978. Cited by 141 papers, by iCite.
Cite this record
ConductScience Library. In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Papers, record 75339. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/75339
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acetylcholine | Major topic |
| Autoantibodies | Major topic |
| Myasthenia Gravis | Major topic |
| T-Lymphocytes | Major topic |
| Thymus Gland | Major topic |
| Adolescent | |
| Adult | |
| Cells, Cultured | |
| Humans | |
| In Vitro Techniques |
Source PubMed
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 141 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42427480 | Pathobiology of thymic epithelial tumours and the treatment strategy based on immuno-oncological characteristics: a narrative review. | Mediastinum | 2026 | https://conductscience.org/library/papers/42427480 | PubMed |
| 41981116 | Morphometric analysis of the thymic epithelial cell network using integrated and orthogonal digital pathology approaches. | Commun Biol | 2026 | https://conductscience.org/library/papers/41981116 | PubMed |
| 41164186 | Thymus research in relation to myasthenia gravis: a new perspective on cell subpopulations and future directions. | Front Immunol | 2025 | https://conductscience.org/library/papers/41164186 | PubMed |
| 40889171 | Distribution of Ectopic Germinal Centers in Thymic Epithelial Tumors and Their Relationship With Thymic Involution. | Cancer Sci | 2025 | https://conductscience.org/library/papers/40889171 | PubMed |
| 40666538 | Thymic hyperplasia in myasthenia gravis: a narrative review. | Mediastinum | 2025 | https://conductscience.org/library/papers/40666538 | PubMed |
| 40625741 | Thymic B cells in aging and autoimmune disease. | Front Immunol | 2025 | https://conductscience.org/library/papers/40625741 | PubMed |
| 35942663 | Novel pathophysiological insights in autoimmune myasthenia gravis. | Curr Opin Neurol | 2022 | https://conductscience.org/library/papers/35942663 | PubMed |
| 35389099 | Seronegative myasthenic crisis: a multicenter analysis. | J Neurol | 2022 | https://conductscience.org/library/papers/35389099 | PubMed |
| 35165857 | Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management. | Neurotherapeutics | 2022 | https://conductscience.org/library/papers/35165857 | PubMed |
| 34790201 | The Multifaceted Roles of B Cells in the Thymus: From Immune Tolerance to Autoimmunity. | Front Immunol | 2021 | https://conductscience.org/library/papers/34790201 | PubMed |
| 34071155 | Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34071155 | PubMed |
| 33774709 | Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. | Acta Neuropathol | 2021 | https://conductscience.org/library/papers/33774709 | PubMed |
| 33537838 | Thymus and autoimmunity. | Semin Immunopathol | 2021 | https://conductscience.org/library/papers/33537838 | PubMed |
| 33199596 | Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. | Proc Natl Acad Sci U S A | 2020 | https://conductscience.org/library/papers/33199596 | PubMed |
| 32547535 | Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. | Front Immunol | 2020 | https://conductscience.org/library/papers/32547535 | PubMed |
| 31269763 | Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. | Cells | 2019 | https://conductscience.org/library/papers/31269763 | PubMed |
| 30762205 | Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status. | Drugs | 2019 | https://conductscience.org/library/papers/30762205 | PubMed |
| 28940642 | B cells in the pathophysiology of myasthenia gravis. | Muscle Nerve | 2018 | https://conductscience.org/library/papers/28940642 | PubMed |
| 28429039 | [True thymic hyperplasia : Differential diagnosis of thymic mass lesions in neonates and children]. | Pathologe | 2017 | https://conductscience.org/library/papers/28429039 | PubMed |
| 26510558 | Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. | Neurotherapeutics | 2016 | https://conductscience.org/library/papers/26510558 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/75339
GET https://conductscience.org/api/papers/v1/75339/cited_by?page=2